On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids.
On June 16, 2010, Neurocrine reached an agreement with AbbVie Inc. (formerly Abbott Laboratories) worth up to $575 million, granting AbbVie the global rights to develop and market elagolix, a pill that blocks GnRH hormones to treat endometriosis and uterine fibroids.